MoonLake Immunotherapeutics (NASDAQ: MLTX) — Perfil da empresa, notícias e dados financeiros
MoonLake Immunotherapeutics creates therapies for immune-mediated diseases like psoriasis and inflammatory bowel disease.
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics (NASDAQ:MLTX) focuses on revolutionizing the treatment landscape for patients with immune-mediated diseases. This entails developing innovative therapies that can significantly improve quality of life and outcomes for those suffering from conditions like psoriasis, inflammatory bowel disease, and other chronic autoimmune conditions. MoonLake aims to harness the power of cutting-edge science and technology to create drugs that can effectively target and modulate the immune system, providing new hope for patients with limited treatment options. With a commitment to rigorous research and clinical development, MoonLake is steadfast in its mission to bring groundbreaking therapies from the lab bench to the bedside, striving to lead a new era in immunotherapy.
Resumo
Operações
Produtos e/ou serviços de MoonLake Immunotherapeutics
- Development of sonelokimab for various inflammatory diseases, focusing on psoriasis, psoriatic arthritis, and ankylosing spondylitis.
- Innovative treatments based on Nanobody technology targeting immune-mediated diseases.
- Partnerships for research and development in dermatology and rheumatology.
- Expansion of the Nanobody technology platform for broader therapeutic applications.
- Customized clinical development programs for immune-mediated inflammatory conditions.
- Pipeline development of next-generation biologics for autoimmune diseases.
equipe executiva do MoonLake Immunotherapeutics
- Jorge Santos da SilvaCo-Founder, Interim Chair of the Board & CEO
- Kristian ReichCo-Founder & Chief Scientific Officer
- Matthias BodenstedtChief Financial Officer
- Oliver DaltropChief Technical Officer
- Carla BretesDirector of Investor Relations & External Communications
- Nicolas MosimannGeneral Counsel
- Joana CortezAssociate Vice-President of Legal & Compliance
- Tino AnthamattenVice President of Marketing, Market Access & Pricing
- Luciana MarquesAssociate Vice-President of HR, People and Culture
- Nuala BrennanChief Clinical Development Officer
Principais indicadores financeiros
Resultados divulgados pela MoonLake Immunotherapeutics, em USD.
- Cap. de mercado
- 1 bi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -3.8
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -244,8 mi | -227,3 mi | |
| 0 | -143,1 mi | -118,9 mi | |
| 0 | -54,1 mi | -36 mi | |
| 0 | -65,1 mi | -64,5 mi |